Calling it "one of the most significant unresolved legal questions currently affecting the pharmaceutical industry," Merck & Co. Inc. hit the pay-for-delay ball into the Supreme Court, asking the court to, once and for all, determine whether the reverse settlements violate federal antitrust laws.